NanoBio Corporation and the University of Michigan to Receive $9.3M from the National Institutes of Health (NIH) for Nanoemulsion-Based Vaccine Development

ANN ARBOR, Mich.--(BUSINESS WIRE)--NanoBio Corporation today announced an award from the National Institute of Allergy and Infectious Diseases, a Division of The National Institute of Health, to fund vaccine research associated with “Innate Immune Receptors and Adjuvant Discovery.” NanoBio is the principal subcontractor for the $9.3 million contract awarded to the University of Michigan. NanoBio will receive a subcontract of approximately $4.1 million over the research period to support efforts aimed at developing nanoemulsion-based mucosal vaccine adjuvants for a wide variety of antigens.